Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06678841). This is a study registration, not published results. Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 700 participants (ESTIMATED). Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF). Interventions: DEVICE: Personalized cardiac pacing. Primary outcome measures: Primary Efficacy Objective: Hierarchical composite endpoint of cardiovascular mortality, urgent HF events, HF events requiring an oral diuretic intensification (ODI), change in KCCQ, change in six-minute walk test distance, and change in NT-proBNP. , Follow-up duration for endpoint analysis is 12-months.; Primary Safety Objective: Percentage of patients with major complications related to the system or procedure. , 12-months post pacemaker implant attempt.. Brief summary: ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).